Clinical Trials

Study Title:
A Phase 3 Randomized Study of Selumetinib (IND # 77782) Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low Grade Glioma (LGG)

For more information about the trial above please contact the study team:

Principal Investigator, Jacqueline Kraveka, at kravekjm@musc.edu.

Study Coordinator, Jared Hortman, at hortman@musc.edu.

Trial opened at the following institutions: Medical University of South Carolina